Sort   by:  
 Page size 
ProteomicsProteome analysis of Mel426 melanoma cells with R2PD1 treatment
A label-free quantification experiment was performed to study the effect of R2PD1 chimeric protein treatment on the cellular proteome of Mel426 human melanoma cells. Peptides were separated by online reverse phase liquid chromatography and measured in an Exploris 480 Orbitrap mass spectrometer. Mas...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2023-03-16 | MSV000091500 | MassIVE
Genomicsena-DATASET-DKFZ-HIPO-04-02-2020-14:25:47:776-113 - samples
This dataset contains 3 pairs of exomes, germline (from whole blood) and patient-derived xenograft (PDX), from human pancreatic durctal adenocarcinoma patients. The data is referred to in the publication: "Pro-immunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory a...
EGAD00001005938 | EGA
Genomicspancreatic ductal adenocarcinoma exomes in study: Pro-immunogenic Impact of MEK inhibition combined with an anti-CD40 immunostimulatory antibody
Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression ...
EGAS00001004196 | EGA
TranscriptomicsGene expression profiling of antigen-specific T cells upon CCR9 knockdown in MCF7 cells.
Tumor cells are known to express immune-inhibitory ligands on their surface to mediate resistance against cytotoxic T lymphocytes. Using a high-throughput RNAi screening assay, we identified CCR9 as a potent tumor-specific immune checkpoint molecule that inhibited T cell-mediated tumor lysis. To und...
ORGANISM(S): Homo sapiens 
2015-02-19 | E-MTAB-3244 | biostudies-arrayexpress
Sort   by:  
 Page size